Patents for A61K 49 - Preparations for testing in vivo (35,376)
09/2004
09/30/2004WO2004082721A1 Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes
09/30/2004WO2004082517A2 Animal exhibiting ptsd-like behavior, per pct rule 4.3
09/30/2004WO2004064768A3 Animal model for alzheimer's disease
09/30/2004WO2004062568A3 Conjugate of losartan, valsartan, candesartan or eprosartan and a chelant as contrast agent
09/30/2004WO2004053504A3 Particles for imaging cells
09/30/2004US20040193044 Tissue site markers for in vivo imaging
09/30/2004US20040193040 Method for imaging a metabolic event of an organism
09/30/2004US20040192776 Cationic lipid compositions targeting angiogenic endothelial cells
09/30/2004US20040192645 detecting chitin in mammals; useful for diagnosing disease caused by accumulation of chitin or amyloid plaques such as Alzheimer's disease, spongiform encepalopathies, type II diabetes, atrial amyloidosis; administering the composition to inhibit polymerization of N-acetylglucosamine to chitin
09/30/2004US20040191898 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy
09/30/2004US20040191320 Pulmonary formulation
09/30/2004US20040191175 Radio-Opaque polymer biomaterials
09/30/2004US20040191173 Metastasis models using green fluorescent protein (GFP) as a marker
09/30/2004US20040191172 Preventive or therapeutic agents for dermatitis or alopecia, evaluation method of the agents, and transgenic mouse
09/30/2004US20040191171 Method of detecting skin stimulation effect
09/30/2004US20040191170 Evaluation of infections by enteric pathogens including diarrhea caused by Escherichia and are hemorrhagic
09/30/2004CA2519324A1 Medical devices with enhanced ultrasonic visibility
09/30/2004CA2519315A1 Radiolabeled conjugates based on substance p and the uses thereof
09/29/2004EP1462119A1 Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
09/29/2004EP1462118A1 Compositions including a visual marker and method of use thereof
09/29/2004EP1462117A1 Method for in vivo detection of antipsychotic properties of dopamine D3 receptor ligands
09/29/2004EP1461449A2 System for monitoring bacterial tumor treatment
09/29/2004EP1461443A2 Carbohydrate-associated proteins
09/29/2004EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
09/29/2004EP1460982A1 Methods for initiating in situ formation of hydrogels
09/29/2004EP1372633B1 Irrigating fluid comprising nitrous oxide
09/29/2004EP1178838B1 Macromolecular carrier based on dextran for drug and diagnostic agent delivery
09/29/2004EP0742831B1 Transgenic non-human mammals with progressive neurologic disease
09/29/2004EP0699079B1 Bioactive and/or targeted dendrimer conjugates comprising genetic materials
09/29/2004EP0675903B1 Bone resorption assay
09/29/2004EP0616508B2 Gas filled liposomes and their use as ultrasonic contrast agents
09/29/2004CN1533381A Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
09/29/2004CN1533335A Nonskid device for wheels of vehicles
09/29/2004CN1533286A Macrocyclic metal complexes and use thereof for production of conjugates with biomolecules
09/29/2004CN1168741C Monoclonal antibody anti alpha; V-integrin and it use to inhibit alpha; beta; 6-integrain attachment to fibronectine
09/28/2004US6797521 Fluorescent cobalamin for use in the diagnosis and imaging of cancer
09/28/2004US6797464 Detection of drug-resistant human immunodeficiency virus
09/28/2004US6797257 Suitable for use as a contrast agent with a plurality of imaging modalities, including, for example, ultrasound, magnetic resonance imaging, and computed temography; neutron capture therapy
09/28/2004US6797256 Composition for monitoring the metabolism of pyrimidines
09/28/2004US6797255 Methods and compositions for enhancing magnetic resonance imaging
09/26/2004CA2461281A1 Compositions including a visual marker and method of use thereof
09/23/2004WO2004081574A2 Detection, monitoring and treatment of cancer
09/23/2004WO2004081198A2 Methods for modulating angiogenesis with apelin compositions
09/23/2004WO2004081037A1 Inhibitors of extracellular hsp90
09/23/2004WO2004081031A2 Thiol-mediated drug attachment to targeting peptides
09/23/2004WO2004080503A1 Compositions for use in embolizing blood vessels comprising high levels of contrast agent
09/23/2004WO2004080491A1 Agent for detecting sentinel lymph node and detection method
09/23/2004WO2004080483A1 Targeted agents for both photodiagnosis and photodynamic therapy
09/23/2004WO2004080416A2 Animal model simulating neurologic disease
09/23/2004WO2004080335A2 Method for continuous visualization of a body lumen
09/23/2004WO2004080285A2 Amyloid plaque as a target for therapeutics that function by blocking or disrupting chitin synthesis or activity
09/23/2004WO2004063354A3 Compositions and methods for characterizing and regulating wnt pathways
09/23/2004WO2004060052A3 Transgenic mice expressing human cd20 and/or cd16
09/23/2004WO2004051265A3 Fish disease models and uses thereof
09/23/2004WO2004024877A3 Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent
09/23/2004WO2004016751A3 Methods of treating neurodegenerative diseases
09/23/2004US20040187172 Transgenic animal for screening therapeutic agents for brain tumors
09/23/2004US20040187169 Identifying genes which effect cardiac function after or during oxygen deprivation for imaging and measuring movements of the heart; fluorescent microscopy; animal model for human heart disease
09/23/2004US20040186063 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
09/23/2004US20040186045 Compositions and methods for enhancing drug delivery across and into epithelial tissues
09/23/2004US20040185510 Administering a composition sufficient for external imaging, a peptide of given formula; radioactive scanning or by magnetic resonance; use for detecting metastasis; kits
09/23/2004US20040185431 for drug screening anticancer agents using animal model expression profiles; genetic engineering
09/23/2004US20040184644 Display for computer-aided evaluation of medical images and for establishing clinical recommendation therefrom
09/23/2004CA2523605A1 Targeted agents for both photodiagnosis and photodynamic therapy
09/23/2004CA2518944A1 Inhibitors of extracellular hsp90
09/23/2004CA2518783A1 Detection, monitoring and treatment of cancer
09/23/2004CA2518407A1 Animal model simulating neurologic disease
09/23/2004CA2518406A1 Thiol-mediated drug attachment to targeting peptides
09/23/2004CA2510678A1 Compositions for use in embolizing blood vessels comprising high levels of contrast agent
09/22/2004EP1458863A1 A system for stable expression of sirnas in mammalian cells
09/22/2004EP1458328A2 Formulations for use in medical or diagnostic procedures
09/22/2004EP1173766B1 A tenascin-c isoform as a marker for neoplasias
09/22/2004EP1096955B1 Uses of antibodies to aminophospholipids for cancer treatment
09/22/2004EP1069888B1 Use of particulate contrast agents in diagnostic imaging for studying physiological parameters
09/22/2004EP0929319B1 Dopamine and serotonin transporter ligands and imaging agents
09/22/2004EP0882055B1 Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
09/22/2004CN1531554A Humanized antibodies derived from DD-3B6-22, specific for D-dimer fragment of fibrin
09/22/2004CN1531439A Liposome targeting of matrix metalloproteinase inhibitors
09/21/2004US6794518 Vitronectin receptor antagonist pharmaceuticals
09/21/2004US6793924 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated t cells and thereby inhibits t cell activation of b cells
09/21/2004CA2141839C Magnetic resonance arteriography with dynamic intravenous contrast agents
09/18/2004CA2433205A1 Drug delivery, bodily fluid drainage, and biopsy device with enhanced ultrasonic visibility
09/16/2004WO2004078985A1 Animal model for the fast identification of pharmaceutical active compounds in vivo
09/16/2004WO2004078984A1 Animal model for the fast identification of pharmaceutical active compounds in vivo
09/16/2004WO2004078927A2 Progenitor cells and methods of using same
09/16/2004WO2004078778A2 PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
09/16/2004WO2004078027A2 Materials and methods for near-infrared and infrared intravascular imaging
09/16/2004WO2004062627A9 In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders
09/16/2004WO2004054637A3 Contrast media formulations having improved biological tolerance
09/16/2004WO2004041328A3 Pharmaceutical identification
09/16/2004WO2004013180A3 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
09/16/2004WO2003086299A3 Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
09/16/2004WO2003065971A3 Non-myeloablative tolerogenic treatment with tyrphostins
09/16/2004US20040181147 Method and apparatus for administration of contrast agents for use in magnetic resonance arteriography
09/16/2004US20040181114 Methods of enhancing radiation effects with metal nanoparticles
09/16/2004US20040180943 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
09/16/2004US20040180834 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
09/16/2004US20040180828 Apoptosis suppression; polypeptides of sequence 2 having surface groove including amino acid residues P325, G326, H343 and L344
09/16/2004US20040180823 Peptides, peptidomimetics; promoting programmed cell death; neural regeneration
09/16/2004US20040180817 Use of tumor necrosis factor alpha p75 receptor antagonist or endothelin receptor antagonist, converting enzyme inhibitor or neutralizing agent; reducting cerebral perfusion; method of identifying candidates